SPRO
Spero Therapeutics Inc
NASDAQ: SPRO · HEALTHCARE · BIOTECHNOLOGY
$2.51
-0.79% today
Updated 2026-04-30
Market cap
$154.60M
P/E ratio
17.80
P/S ratio
2.31x
EPS (TTM)
$0.15
Dividend yield
—
52W range
$1 – $3
Volume
0.4M
Spero Therapeutics Inc (SPRO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
12.80%
Operating margin
76.00%
ROE
16.30%
ROA
4.99%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | $0.00 | $-10.15M | — | — | — |
| 2016 | $335000.00 | $-25.49M | -7,760.60% | -9,916.72% | -7,609.25% |
| 2017 | $1.98M | $-46.10M | 100.00% | -2,108.64% | -2,329.31% |
| 2018 | $3.97M | $-41.66M | 100.00% | -1,079.32% | -1,050.48% |
| 2019 | $4.74M | $-60.17M | 100.00% | -1,333.11% | -1,268.98% |
| 2020 | $9.33M | $-77.52M | 100.00% | -847.94% | -830.86% |
| 2021 | $3.07M | $-89.76M | 100.00% | -2,865.50% | -2,923.65% |
| 2022 | $48.58M | $-46.41M | 100.00% | -86.86% | -95.55% |
| 2023 | $103.78M | $22.81M | 50.43% | 20.70% | 21.98% |
| 2024 | $47.98M | $-68.57M | -101.67% | -152.91% | -142.91% |
| 2025 | $59.62M | $8.57M | 100.00% | -0.04% | 14.38% |